EglenMed Honored with BioTech Breakthrough Award for Drug Development Innovation

"From the very beginning of our pipeline's establishment, we have set internationalization as our goal, oriented by technological innovation. We utilize self-developed AI technology to overcome traditional bottlenecks in clinical R&D, and align our development strategies with highly regulated markets such as the U.S. and Europe, forming an efficient and collaborative global R&D landscape. In the future, we will continue to deepen strategic cooperation with overseas research institutions and pharmaceutical companies, allowing the R&D achievements of China's innovative drugs to benefit patients worldwide."Dr. Tao Du, Founder and Chairman of Evergreen Therapeutics, stated。

Unlike most AI pharmaceutical companies that focus on the front end of drug discovery, Evergreen Therapeutics innovatively places its technical emphasis on the clinical stage — a "bottleneck area" in the industry’s R&D process. The company's self-developed AI platform features three core engines: cross-species translational prediction, mechanism prioritization, and "target-population-disease" mapping. By systematically uncovering molecular mechanisms and validating therapeutic hypotheses, it enables more precise target identification, deeper understanding of disease mechanisms, and optimized clinical trial design, helping users make faster decisions and improve clinical trial outcomes. The integration of AI technology significantly enhances the success rate of candidate drugs entering clinical trials, effectively reduces R&D costs, and shortens timelines, addressing long-standing pain points that have troubled the pharmaceutical R&D industry.

This unique R&D model has been fully validated in the clinical research of Evergreen Therapeutics' core pipeline.On October 26, Evergreen Therapeutics announced the breakthrough results of the Phase II clinical study of its pipeline drug EG-501.The drug is used to treat cognitive impairment caused by neuropsychiatric systemic lupus erythematosus (NPSLE). Studies have shown that the improvement in the total score of the RBANS (Repeatable Battery for the Assessment of Neuropsychological Status) in the EG-501 group was significantly better than that in the placebo group. The success of the Phase II clinical trial not only demonstrated the potential of EG-501 as the first therapy for cognitive impairment in NPSLE, but also completed the full closed loop from prediction to clinical validation on the platform, providing the industry with a scalable and repeatable drug development paradigm.

Currently, Evergreen Therapeutics has received FDA approval for six pipelines to enter clinical stages, maintaining a leading position in the global AI pharmaceuticals field. The company has established a dual business model of "proprietary pipelines + technical services": while rapidly advancing its own pipelines, Evergreen Therapeutics also leverages its mature AI R&D technology and extensive international clinical regulatory experience to provide flexible and efficient R&D solutions for partners, helping Chinese novel drugs reach the global market.